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The human papillomaviruses associated with cervical cancer (e.g., HPV-16 and HPV-18) express an E7 oncoprotein which
mediates the immortalization of primary genital keratinocytes and the transformation of rodent cells. The 105-amino-acid
HPV-18 E7 protein contains two zinc fingers as well as a conserved amino-terminal motif (Rb-binding core) which binds
and alters the interactions of the retinoblastoma susceptibility gene product (Rb). We report here that two serine protease
inhibitors, tosyl-L-lysine chloromethyl ketone (TLCK) and tosyl-L-phenylalanine chloromethyl ketone (TPCK), reacted with and
generated an altered form of the HPV-18 E7 protein. Chemical modification of the E7 protein was initially observed during
its extraction and immunoprecipitation from mammalian cells but could also be detected using E7 protein expressed in
vitro by reticulocyte lysates. More importantly, TLCK and TPCK were able to modify E7 protein in live keratinocytes following
their addition to the culture medium. Site-specific mutagenesis demonstrated that the E7 Rb-binding core (Leu-X-Cys-X-Glu)
contained a cysteine residue which was essential for this modification and that the TLCK/TPCK-dependent alteration of E7
protein abolished its ability to bind Rb. These studies indicate that the E7 protein can be inactivated by a specific class of
protease inhibitors and that such reagents may be useful for pharmacologically regulating E7 function in vivo. In addition,
these results demonstrate that care must be taken when applying these commonly used protease inhibitors in experiments
evaluating E7/cellular protein interactions. q 1996 Academic Press, Inc.
INTRODUCTION genes (Barbosa and Schlegel, 1989; Bedell et al., 1987,
1989; Chesters and McCance, 1989; Halbert et al., 1992;
Human papillomaviruses (HPVs) are small epithelio-
Kanda et al., 1988, 1987; Mu¨nger et al., 1989; Storey et
tropic DNA viruses which induce the proliferation of kera-
al., 1988; Vousden et al., 1988; Yasumoto et al., 1986).
tinocytes. Currently there are more than 100 known HPV
The E6 gene encodes a protein which associates with
types which are associated with a variety of site-specific
the cellular p53 tumor suppressor protein (Werness et
lesions. For example, HPV-1, -2, and -4 induce warts on
al., 1990) and targets it for degradation via the ubiquitin-
the hands and feet; HPV-5 and -8 induce flat warts of the
dependent proteolytic pathway (Scheffner et al., 1994,
epidermis in patients with epidermodysplasia verruci-
1990). However, while it appears that E6 and E7 are
formis; and HPV-6, -11, -16, and -18 induce flat or condy-
necessary for the efficient immortalization of human geni-
lomatous warts on genital mucosa (for review see deVil-
tal keratinocytes, the E7 gene can independently, but
liers, 1989). A subgroup of the genital HPVs, the desig- less efficiently, induce keratinocyte immortalization when
nated ‘‘high risk’’ types (e.g., HPV-16 and -18), are highly transduced into recipient cells via a retrovirus (Halbert
associated with the development of cervical dysplasia et al., 1991). The E7 protein, similar to the SV40 large T
and cervical carcinoma, whereas the ‘‘low risk’’ HPV types and the adenovirus E1A protein, binds the retinoblastoma
(e.g., HPV-6 and -11) are seldom found in malignant tu- susceptibility gene product (Rb) (Dyson et al., 1989) as
mors of the genital tract but are frequently present in well as the related p107 protein (Davies et al., 1993) and
benign cervical lesions (zur Hausen, 1991). alters the ability of the former to interact functionally with
The HPVs which are associated with cervical cancer the E2F transcription factor (Imai et al., 1991). As a conse-
are also uniquely capable of immortalizing and altering quence of E7 binding, E2F is displaced from Rb, thereby
the differentiation of human keratinocytes in vitro (Du¨rst permitting the potential transcriptional activation of cellu-
et al., 1987; McCance et al., 1988; Pirisi et al., 1987; lar genes containing the E2F binding motif in their pro-
Schlegel et al., 1988). In both human and rodent cells, moter regions such as c-myc, c-myb, and cdc-2 (Dalton,
the immortalizing and/or transforming functions of these 1992; Mudryi et al., 1990).
‘‘high risk’’ HPV types map genetically to the E6 and E7 Expression of the E7 protein is both necessary and
sufficient for the immortalization of human genital kera-
tinocytes (Halbert et al., 1991). However, in contrast to1 To whom reprint requests should be addressed. Fax: (202) 687-
5285. rodent cell systems where E7–Rb binding appears to be
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critical for cellular transformation (Barbosa et al., 1990; kinase inactivation is accompanied by the alkylation of
a sulfhydryl-containing amino acid residue in the enzymeGage et al., 1990; Heck et al., 1992; Sang and Barbosa,
1992), E7–Rb interaction is not essential for the immor- active center. The demonstrated inability of a TLCK-modi-
fied E7 protein to bind Rb suggests the possibility oftalization of human genital keratinocytes (Jewers et al.,
1992). These findings suggest that there are additional designing molecular therapeutics which modulate the
interactions between the E7 protein and ‘‘pocket proteins’’critical targets for the E7 protein, potentially including
Rb-related proteins which have not yet been identified. (e.g., Rb, p107).
For example, the E7 protein has been shown to deregu-
late B-myb gene expression by interacting with p107 MATERIALS AND METHODS
(Lam et al., 1994) as well as to bind the cell cycle regula-
Plasmid construction
tory protein, cyclin A (Tommasino et al., 1993). It has
further been shown that in E6/E7-immortalized cell lines The plasmid pURR18E6/7rAU1 was obtained by clon-
ing a polymerase chain reaction (PCR)-generated HPV-(as in other DNA tumor virus transformed cell lines) a
rearrangement of cyclin-dependent kinase complexes 18 fragment incorporating the URR and the open reading
frames E6 and E7 into the plasmid CCB119 (Villa andoccurs (Xiong et al., 1993) and that in these cells, proba-
bly depending upon the E7–Rb interaction, the function Schlegel, 1991). The 5* primer for the PCR contained 6
random bases followed by a HindIII restriction site, andof cyclin D1 is dispensable during the G1 phase of the
cell cycle (Lukas et al., 1994). the HPV-18 homologous region started at nt 7114 (5*
primer: GTATCAAAGCTTTGCGTGTACGTGCCAGGAAG).Structurally, the E7 protein consists of two conserved
domains (CDI and CDII) which are also found in the The 3* primer anneals to the HPV-18 genome at position
nt 887–904. It carries additionally at its 3* end the codingadenovirus E1A protein and the SV40 large T antigen
(DeCaprio et al., 1988; Moran and Mathews, 1987; Phelps sequence for the AU1 epitope as well as the XhoI restric-
tion site followed by 12 random bases (3* primer: GCTAet al., 1988). CDI encompasses the E7 N-terminus, and
mutations in this region interfere with ras cooperativity CTATCGATCTCGAGTTATATATAGCGATAGGTGTCCT-
GCTGGGATGCACACCA).in the transformation of rodent cells (Banks et al., 1990;
Watanabe et al., 1990). E7 CDI does not participate in The plasmid pSV contains the SV40 origin of replica-
tion along with the SV40 early promoter and polyadenyla-Rb binding, in contrast to CDI of E1A. Rather, Rb binding
by E7 is a function of E7 CDII (Banks et al., 1990; Dyson tion signal. This vector is a derivative of pSG5 (Green et
al., 1988) which contains a modified polylinker. The vec-et al., 1992; Stirdivant et al., 1992; Watanabe et al., 1990)
which is analogous to regions in the SV40 large T protein tor allows for efficient transient expression of proteins in
cells expressing large T antigen such as COS cells. Theand the adenovirus E1A protein.
We report here that the HPV-18 E7 Rb-binding core HPV-18 E7 protein was amplified by PCR with the AU1
epitope tag at the carboxyl-terminus and inserted down-resembles the active center of trypsin/chymotrypsin ser-
ine proteases by its reaction with specific inhibitors of stream of the SV40 early promoter in pSV. The 5* primers
for all cloned E7 genes contained 6 random bases, thethese proteases. Our initial observation that the E7 pro-
tein immunoprecipitated from eukaryotic cells existed in restriction site sequence EcoRI (only in the case of the
His2 to Asp mutant a HindIII site) followed by the Kozaktwo distinct molecular weight forms led us to discover
that both tosyl-L-phenylalanine chloromethyl ketone consensus sequence (Kozak, 1987), and the homologous
HPV-18 region beginning at position nt 590. The 3* prim-(TPCK) and tosyl-L-lysine chloromethyl ketone (TLCK) re-
acted with E7 and generated a modified form of the E7 ers contained the DNA sequence encoding the AU1 epi-
tope and the HindIII restriction site sequence followedprotein in vitro and in vivo. The TLCK/TPCK-altered E7
protein migrated slightly faster (15 kDa) in SDS–PAGE by 6 random bases. Mutations were introduced in the
HPV-18 E7 open reading frame using a single or doublethan the native E7 protein (17 kDa). The reactivity of E7
with TPCK and TLCK was strictly dependent upon the PCR. DNA sequences of all clones were verified using
Sequenase version 2.0 (U.S. Biochemical) with sense-presence of a conserved cysteine residue in the Rb-
binding core and interfered with the Rb binding of the and antisense-strand primers derived from the pSV vec-
tor. Primer sequences for single PCR were as follows:E7 protein.
TLCK and TPCK are known serine protease inhibitors wild-type HPV-18 E7, 5* ACGAGTGAATTCGCCACCATG-
CATGGACCTAAGGCAACATTGC (primer 1), 3* GCTACT-which alkylate a histidine sidechain in the active center
of their target proteases (Schoellmann and Shaw, 1963; AAGCTTTTACTGCTGGGATGCACACCA (primer 2); His2
to Asp, 5* AGCAGTAAGCTTGCCACCATGGATGGACCT-Shaw, 1970), trypsin (TLCK) and chymotrypsin (TPCK).
While this alkylation reaction is highly specific for trypsin AAGGCAACATTG (primer 3), 3* primer 2; Cys89 to Ser,
5* primer 1, 3* ATCGATCTCGAGTTATATATAGCGATA-and chymotrypsin proteases, cAMP-dependent kinase
and protein kinase C (Kinzel and Ko¨nig, 1980; Kupfer et GGTGTCCTGCTGGGATGCACACCACGGACTCACAAA-
GGACAGGGTG (primer 4); Leu13 to Thr, 5* ACGAGT-al., 1979; Lalou and Lederer, 1993; Solomon et al., 1985)
are also modified and inactivated by TPCK/TLCK appar- GAATTCGCCACCATGCATGGACCTAAGGCAACATTG-
CAAGACATTGTAACGCATTTAGAGCCC (primer 5), 3*ently due to the presence of a conserved active site. The
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primer 2. Primer sequences for double PCRs were as the HPV-18 E6/7 genes (Villa and Schlegel, 1991). Follow-
ing transfection, the cells were passaged in P4-8F me-follows: Cys29 to Gly, PCR1 5* GACCTTCTAGGTCAC-
GAGCAATTAAGCGAC (primer 6), 3* primer 2/5* primer dium (BRFF) to select for immortalized cells.
1, 3* CTCGTGACCTAGAAGGTCAACCGGAATTTC (primer
Transfection of COS cells7); PCR2 5* primer 1, 3* primer 2. His59 to Ala, PCR1 5*
CAACGTGCCACAATGTTGTGTATGTGTTGTAAG (primer
For transfection of pSV constructs into COS cells, a
8), 3* primer 2/5* primer 1, 3* ACACAACATTGTGGCACG-
modified calcium phosphate method was employed.
TTGTGGTTCGGCTCGTCGGGCTGG (primer 9); PCR2 5*
Briefly, 3 1 105 COS cells were plated in 10-cm-diameter
primer 1, 3* primer 2. Cys65, 66 to Ser, PCR1 5* GTTGTG-
dishes. Ten micrograms of the particular pSV DNA was
TATGTCTTCTAAGTGTGAAGCCAGAATTG (primer 10), 3*
dissolved in 219 ml water, and 31 ml 2 M CaCl2 wasprimer 2/5* primer 1, 3* CTTCACACTTAGAAGACATAC-
added. The mixture was added dropwise with mixing to
ACAACATTGTGTGAC (primer 11); PCR2 5* primer 1, 3*
250 ml 21 HEPES-buffered saline (280 mM NaCl, 10 mM
primer 2. Cys 65, 66, 98 to Ser, PCR1 5* primer 10, 3*
KCl, 1.5 mM Na2HPO4 , 15 mM dextrose, and 50 mMprimer 2/5* primer 1, 3* primer 4; PCR2 5* primer 1, 3*
HEPES), pH 7.05. The mixture was allowed to incubate
primer 4.
30 min at room temperature and then was added to the
COS cells in 2.5 ml DMEM with 10% FBS and incubatedCells and cell culture
at 377. After 16–18 hr cells were shocked for 60 sec with
Primary human foreskin keratinocytes were pre- 15% glycerol in 11 HEPES-buffered saline, washed three
pared using described techniques (Yuspa and Harris, times with phosphate-buffered saline (PBS), and further
1974) and were cultured in keratinocyte serum-free incubated in DMEM plus 10% fetal bovine serum for 48
medium (KSFM; Gibco-BRL). COS cells were grown in hr until cell harvesting.
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). Immortal- Radiolabeling and immunoprecipitation of E7 proteins
ized human keratinocyte lines were maintained in 3/1
Transfected COS cells or keratinocyte cell lines weremedium (three parts KSFM plus one part DMEM with
washed with PBS, incubated with 2 ml of cysteine- and10% FBS). The human prostate cell line was grown in
methionine-free DMEM (COS cells) or with cysteine-freeP4-8F medium (BRFF, Ijamsville, MD).
DMEM (keratinocytes and prostate cells) for 1.5 hr and
labeled for 4 hr by addition of 430 mCi of a mixture ofLipofection of primary keratinocytes
approximately 75% 35S-labeled methionine and 25% cys-
To immortalize human primary keratinocytes we used teine (Pro-Mix, Amersham) (COS cells) or 500 mCi of [35S]-
a selective keratinocyte assay (Schlegel et al., 1988). cysteine (Amersham) (immortalized keratinocytes and
Primary human keratinocytes in 10-cm-diameter dishes prostate cells) at 377. Cells were washed twice in PBS
were grown to 50% confluence in KSFM (Gibco-BRL) and and extracted in 1 ml of a modified RIPA buffer [20 mM
transfected with 10 mg plasmid DNA using 50 ml lipofectin MOPS (morpholinepropanesulfonic acid), 150 mM NaCl,
reagent (Gibco-BRL) in 1 ml KSFM. After 2 hr incubation 1% Nonidet-P40, 1% deoxycholate, and 0.1% sodium do-
at 377, 9 ml KSFM was added and the cells were cultured decyl sulfate (SDS), pH 7.2] containing or omitting prote-
until they reached confluency. Confluent dishes were ase inhibitors (TLCK, TPCK; Boehringer Mannheim
split into 162-cm2 flasks and maintained on KSFM until GmbH) at a final concentration of 0.135 mM TLCK and
the cell monolayer was again confluent. The cultures 0.280 mM TPCK. For extraction buffers containing higher
were then changed into DMEM containing 10% FBS and TLCK concentrations, a Nonidet-P40-based extraction
1 mg/ml hydrocortisone and cultivated for an additional buffer was used (0.1% NP-40, 250 mM NaCl, 50 mM
2–4 weeks. The change in medium increases the serum HEPES, pH 7.0). After 5 min of shaking (47), extracts were
and calcium concentration which induces keratinocyte centrifuged for 2 min in an Eppendorf microcentrifuge
differentiation. Immortalized keratinocytes display a re- (47). Appropriate antibody [5 ml AU1 ascites fluid (BAbCO,
sistance to this induction and appear as plaque-like Berkeley, CA) or 20 ml anti-E7 antiserum (Barbosa and
monolayer colonies against a background of stratified, Schlegel, 1989)] was added to the supernatant along with
differentiated cells (Schlegel et al., 1988). Individual colo- 60 ml of protein A–Sepharose CL-4B beads (Pharmacia).
nies generated by pURR18E6/7rAU1 were cloned, ex- Following 1.5 hr of rotating at 47, Sepharose beads were
panded, and passaged in vitro to verify their immortalized pelleted, washed three times in RIPA buffer with or with-
state. out protease inhibitors (TLCK, TPCK), and resuspended
in 60 ml of sample buffer with 10% b-mercaptoethanol.
Immortalization of human primary prostate cells
For double immunoprecipitations the Sepharose bead
pellet was resuspended in 0.2 ml solubilization bufferThe HPV-18 E6/7-immortalized human prostate cell
line was a kind gift from Dr. E. Gelmann (Lombardi Can- (0.4% SDS, 50 mM triethanolamine–Cl, pH 7.4, 100 mM
NaCl, 2 mM EDTA, 2 mM b-mercaptoethanol) and treatedcer Center, Georgetown University Medical Center) and
was generated by transfecting primary prostate cells with for 2 min at 1007. After cooling, 4 ml iodoacetamide (0.5
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M ) and 50 ml 10% Triton X-100 were added. The samples oxide treated, trichloroacetic acid precipitated, and
counted in a scintillation counter.were pelleted and the supernatant was removed for im-
munoprecipitation with the second antibody. Appropriate The in vitro-synthesized E7 proteins (2.4 1 106 cpm)
were divided into two samples and each diluted up toantibody and protein A–Sepharose beads were added
and the mixture was incubated with rotation for a further 2.0 ml in Nonidet-P40 buffer and incubated for 1 hr at 47
with or without 1.1 mM TLCK. Subsequently, in order tohour at 47. Beads were then pelleted, washed with PBS,
and resuspended in sample buffer with b-mercaptoetha- remove excess TLCK the samples were gel filtered on
a Sephadex G50 column. To verify successful in vitronol for electrophoresis. Samples were heated to 1007 for
4 min and analyzed by 12–14% SDS–polyacrylamide gel translation and TLCK-dependent modification, 1.0 ml of
the samples was used for a direct immunoprecipitationelectrophoresis (SDS–PAGE). Gels were fixed with gla-
cial acetic acid–methanol, treated with Enlightning of the E7 protein using the AU1 antibody. The Rb-associa-
tion studies were carried out as follows. Primary human(NEN), dried, and exposed to Kodak XAR-5 film at 0707.
Cells were labeled with [32P]orthophosphate by incu- foreskin keratinocytes (2 1 107 cells) were trypsinized
and pelleted in DMEM containing FCS and then washedbating a 50% confluent 75-cm2 flask of immortalized kera-
tinocytes for 30 min in phosphate-free medium (RPMI, with PBS. The cell pellet was afterward extracted in Noni-
det-P40 buffer containing E7 protein by shaking for 30phosphate-free; Gibco-BRL) before adding 1 mCi of [32P]-
orthophosphate (Amersham) and incubating for an addi- min at 47. The remaining cell debris was pelleted and
the supernatant was incubated for 12 hr at 47 beforetional 2 hr. The immunoprecipitations were carried out
as described above. an immunoprecipitation was performed using the C36
monoclonal anti-Rb antibody (Pharmingen). For control,
1 mg bovine serum albumin (final concentration 1 mg/In vivo modification of E7 protein in keratinocyte cell
ml) was added to the E7 protein rather than keratinocytelines
extract. The immunoprecipitates were separated on a
The TLCK- or TPCK-dependent alteration of the E7 12% SDS–PAGE gel.
protein in live cells was carried out during the metabolic
labeling of the cells. HEPES buffer (final concentration
RESULTS10 mM, pH 7.0) and TPCK or TLCK were added to the
medium 15 to 30 min before the end of the 4-hr labeling HPV-18 E7 protein immunoprecipitated from
period with [35S]methionine/cysteine. After metabolic la- immortalized human keratinocytes migrates in SDS–
beling, cell extraction and immunoprecipitation were car- PAGE as two discrete forms (15 and 17 kDa)
ried out as described, omitting TLCK and TPCK.
A human keratinocyte cell line, HPV-18 NcoI, and a
human prostate cell line, both immortalized by HPV-18Combined immunoprecipitation/Western blot
DNA, were evaluated for E7 expression using a rabbittechnique
polyclonal antibody generated against the HPV-18 E7
Keratinocyte cell lines or transfected COS cells were protein (Barbosa and Schlegel, 1989). The keratinocytes
harvested in 1 ml RIPA buffer with protease inhibitors were metabolically labeled with [35S]cysteine and solubi-
and immunoprecipitated as described above with AU1 lized in RIPA buffer containing a mixture of protease in-
antibody. Samples were electrophoresed on 14% SDS – hibitors, and the extracts were immunoprecipitated with
polyacrylamide gels. The gels were blotted onto PVDF antibody and Staph A Sepharose as previously described
membranes (Millipore) and proteins were detected by a (see Materials and Methods). In order to reduce nonspe-
chemiluminescence (Western-Light, Tropix) kit using the cific background precipitation, the first immunoprecipi-
polyclonal anti-E7 antibody at a dilution of 1:200 as the tate was used in a second round of precipitation (see
primary antibody and goat anti-rabbit alkaline phospha- Materials and Methods, double immunoprecipitation).
tase conjugate (Tropix) at 1:10,000 dilution as the sec- Following SDS–polyacrylamide gel electrophoresis of
ondary antibody. the immunoprecipitates, two distinct proteins (15 and 17
kDa) were observed in the HPV-18-immortalized cell
In vitro expression of the E7 protein and E7–Rb lines but not in a control cell line immortalized by HPV-
association 16 (Fig. 1A). This finding has also been confirmed with
other HPV-18-immortalized cell lines, including the HPV-
The HPV-18 E7 protein was expressed in vitro ac- 18E6E7 cell line (Barbosa and Schlegel, 1989) (data not
cording to the manufacturer’s protocol in a reticulocyte shown).
lysate (Single Tube Protein, Novagen). Two micrograms
of the pSVE7rAU1 plasmid was used to transcribe the A biologically active, epitope-tagged form of E7
E7 gene in vitro. The generated RNA was then translated migrates as 16- and 18-kDa forms
using 80 mCi of 35S-labeled methionine/cysteine (Pro-Mix,
Amersham). To determine the amount of radioactive in- To determine whether the two immunoprecipitated
bands were both E7 protein, we constructed a vectorcorporation, aliquots of the translated material were per-
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FIG. 1. (A) HPV-18 E7 protein immunoprecipitated from immortalized foreskin and prostate cell lines migrates as an apparent doublet on SDS–
PAGE gels. The HPV-18 NcoI keratinocyte cell line, a prostate cell line (both immortalized by HPV-18 DNA), and the 1321 keratinocyte cell line
[(Mu¨nger et al., 1989), immortalized by HPV-16 DNA] were metabolically labeled with [35S]cysteine, extracted in RIPA buffer containing a mixture of
protease inhibitors (see Materials and Methods), and immunoprecipitated with rabbit polyclonal antisera generated against the HPV-18 E7 protein
(Barbosa and Schlegel, 1989). This antiserum does not cross-react with HPV-16 E7 protein. Immunoprecipitates were then dissociated and reimmuno-
precipitated with the rabbit antiserum using conditions described under Materials and Methods in order to reduce background proteins. The final
immunoprecipitates were electrophoretically separated on a 14% SDS–polyacrylamide gel and autoradiographed. Doublet proteins were observed
in the anticipated region of E7 migration (15–17 kDa) only in the HPV-18 NcoI cell line and prostate cell line. Molecular weight markers are indicated
(in kDa) on the left. (B) Both native and epitope-tagged forms of E7 protein migrate as doublets. Keratinocyte cell lines immortalized by HPV-16
DNA (HPV-16 E7), wild-type HPV-18 DNA (HPV-18 E7), or HPV-18 DNA with an AU1 epitope on the E7 gene (HPV-18-E7rAU1) were metabolically
labelled with [35S]cysteine, extracted in RIPA buffer containing protease inhibitors, and immunoprecipitated with either a rabbit polyclonal antiserum
against the HPV-18 E7 protein (anti 18 E7) or against the AU1 epitope (anti AU1) as described under Materials and Methods. The immunoprecipitates
were separated on a 14% SDS – polyacrylamide gel, fixed, and autoradiographed. Arrows indicate the location of the wild-type E7 doublet proteins
(right, lane 4) and the slower migrating, epitope-tagged E7rAU1 doublet proteins (left, lane 2). Molecular weight markers (in kDa) are indicated on
the left.
expressing an epitope-tagged E7 gene (pURR18E6/ bosa and Schlegel, 1989). Regardless of the antibody
employed, two apparent E7 forms were observed in the7rAU1; see Materials and Methods) which would allow
us to utilize a specific monoclonal antibody (AU1) to de- cell lines expressing either wild-type E7 (HPV-18 E7; Fig.
1B, lane 4) or E7rAU1 (HPV-18 E7rAU1; Fig. 1B, lane 2).tect and characterize the synthesized E7 protein.
The E7 expression vector pURR18E6/7rAU1 was de- These two forms were not observed in HPV-16-immortal-
ized keratinocytes which contain a related, but not cross-rived from a wild-type HPV-18 genome by the addition
of an AU1 epitope to the carboxyl-terminus of E7 using reactive, E7 (Fig. 1B, lanes 1 and 3). In addition, these two
proteins were not observed with antibodies generatedPCR techniques. pURR18E6/7rAU1 immortalizing activity
was then evaluated in a quantitative keratinocyte assay against irrelevant proteins (data not shown). The E7rAU1
protein, consistent with the presence of its appended 6-(Schlegel et al., 1988) which is dependent upon the pres-
ence of a functional E7 gene. Addition of the AU1 epitope amino-acid epitope tag, migrated slower (about 1 kDa)
than the wild-type E7 protein in SDS–polyacrylamideto the carboxyl-terminus of E7 did not interfere with its
immortalizing activity and no differences in the immortali- gels. More importantly, it was noted that both forms of
the E7rAU1 protein (Fig. 1B, lane 2) exhibited slowerzation assay were observed comparing the pURR18E6/
7rAU1 vector and a vector containing wild-type E6/7 mobility than the corresponding forms of wild-type E7
(Fig. 1B, lane 4), strongly indicating that both protein spe-(Villa and Schlegel, 1991). Stable HPV-18 E7rAU1-ex-
pressing human foreskin keratinocyte cell lines were es- cies were forms of the E7 protein.
tablished using the pURR18E6/7rAU1 vector.
The immunoprecipitated 16- and 18-kDa proteinsOne of these established lines, K11, was evaluated for
react with E7 antibodies by immunoblot analysisE7rAU1 expression by immunoprecipitation experiments
using the AU1 monoclonal antibody (BAbCO, Berkeley, To verify directly that both immunoprecipitated bands
were E7 protein, we performed a combined immunopre-CA) as well as a rabbit polyclonal anti-E7 antibody (Bar-
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FIG. 2. (A) E7rAU1 doublet proteins react directly with anti-E7 antibodies in an immunoprecipitation–Western blot assay. Cell lines immortalized
with pURR18E6/7rAU1 (HPV-18 E7rAU1) or with the HPV-18 wt genome (HPV-18 E7) were extracted as described above and immunoprecipitated
with AU1 monoclonal antibody (anti AU1). The immunoprecipitates were electrophoretically separated on 14% SDS–PAGE gels, blotted onto a nylon
membrane, and reacted with rabbit polyclonal HPV-18 E7 antiserum (anti E7). Goat anti-rabbit antibodies were used for chemiluminescent detection.
E7rAU1 doublet proteins are indicated on the left and the molecular weight markers (in kDa) on the right. (B) E7rAU1 doublet proteins are labeled
similarly with [32P]orthophosphate. Cell lines K11 (immortalized by pURR18E6/7rAU1) and 1321 (immortalized by HPV-16 DNA) were metabolically
labeled with [32P]orthophosphate, extracted in RIPA buffer containing a mixture of protease inhibitors, and immunoprecipitated with the monoclonal
antibody AU1. The final immunoprecipitates were electrophoretically separated on SDS–polyacrylamide gels and autoradiographed. E7 doublet
proteins were both labeled with [32P]orthophosphate and were detected only in the K11 cell line.
cipitation–Western blot (IP–Western) technique. In this cally, we noted that the addition of two protease inhibi-
tors, TLCK and/or TPCK, led to the appearance of a sec-experiment the E7rAU1 protein was first immunoprecipi-
tated from E7rAU1-expressing cells using the AU1 ond E7 form. When K11 cells were extracted and immu-
monoclonal antibody. After gel separation of the immuno- noprecipitated in the absence of TPCK or TLCK, only one
precipitates and transfer to a nylon membrane, a poly- form (18 kDa) of E7 was detected. In contrast, two spe-
clonal E7 antiserum was applied to detect the E7rAU1 cies of E7 were detected if either TPCK or TLCK or both
proteins in a Western blot assay. As in the previous im- inhibitors were present. In particular, varying the concen-
munoprecipitation experiments, IP–Western blots also tration of TLCK or TPCK in the cell extraction buffer con-
revealed two E7-specific bands (Fig. 2A), confirming that firmed that the alteration of E7 electrophoretic mobility
both protein species were E7. Similar results were also was caused by these protease inhibitors. Figure 3 dem-
found using the polyclonal anti-E7 antiserum for both
the immunoprecipitation and the Western blotting steps
(data not shown).
Once the two protein species had unequivocally been
identified as E7, we attempted to determine whether
phosphorylation might be responsible for generating
these two forms. K11 cells were labeled with [32P]-
orthophosphate, extracted with RIPA buffer containing
protease and phosphatase inhibitors, and immunopre-
cipitated with AU1 monoclonal antibody. Both E7 species
were labeled to a similar level with [32P]orthophosphate
(Fig. 2B), suggesting that gross levels of phosphorylation
did not account for their mobility differences.
Protease inhibitors in the extraction buffer are
responsible for generating the two species of E7
FIG. 3. TLCK converts E7 to a faster migrating species during immu-While evaluating potential modifications of E7 which
noprecipitation. The K11 cell line was metabolically labeled with [35S]-might explain its variant mobilities, we discovered that
cysteine, extracted in Nonidet-P40 buffer containing varying amounts
E7 could be detected as either a single or a double of TLCK, and immunoprecipitated with the monoclonal antibody AU1.
species depending upon the extraction buffer used to Increasing amounts of TLCK in the cell extraction buffer led to an
increasing conversion of the 18-kDa E7 protein to a 16-kDa form.solubilize the cells for immunoprecipitation. More specifi-
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gets for TLCK and TPCK), we also altered amino acids
which have been shown previously to be essential for E7
biological activity (cell transformation and transcriptional
transactivation). The E7 mutants were generated by PCR
and their sequences were verified. A list of the mutants
is presented in Fig. 5 along with a diagrammatic repre-
sentation of the known E7 domains. All mutant proteins
were expressed in the pSVE7rAU1 expression vector
(see Materials and Methods) with the AU1 epitope at
their carboxyl-terminus.
The mutant E7 genes were transfected into COS cells
which were then labeled with [35S]methionine/cysteine
and analyzed by immunoprecipitation in the presence
and absence of TPCK and TLCK. The inhibitor concentra-
FIG. 4. TLCK and TPCK react with E7 protein in vivo. The K11 cell tions in the cell extraction buffer were adjusted to obtain
line was metabolically labeled with [35S]cysteine. Fifteen to thirty min- the nonmodified E7 protein as well as the modified E7
utes before cell harvesting, TPCK or TLCK was added to the tissue
protein (135 mM TLCK, 280 mM TPCK). Mutation of eitherculture medium to the final concentrations indicated. The cells were
histidine 2 to aspartic acid (Fig. 6A, lanes 5 and 6) orthen extracted in RIPA buffer without TLCK and TPCK and immunopre-
cipitated with the monoclonal antibody AU1. Increasing amounts of histidine 59 to alanine (Fig. 6A, lanes 9 and 10) had no
TLCK or TPCK in the tissue culture medium led to increased amounts effect on the ability of TPCK/TLCK to modify E7 protein
of the faster migrating E7 species. mobility. That is, in the presence of TPCK/TLCK, both of
these histidine mutants exhibited two E7 species, similar
to wild-type E7 (Fig. 6A, lane 4). Also, mutation of leucineonstrates the effects of increasing amounts of TLCK in
13 to threonine (Fig. 6A, lanes 7 and 8) had no effect onthe extraction buffer during an immunoprecipitation of
E7 modification by TLCK and TPCK. Several cysteinethe E7 protein from the K11 cell line. The increased
mutants were also unaffected (Fig. 6B). Cysteine 98 toamounts of TLCK in the cell extraction buffer correlate
serine (Fig. 6B, lanes 3 and 4), cysteine 65, 66 to serinewith an increase in the amount of the faster migrating
(Fig. 6B, lanes 5 and 6), and cysteine 65, 66, 98 to serineE7 species (16 kDa).
(Fig. 6B, lanes 7 and 8) exhibited both E7 protein forms
after TPCK and TLCK treatment. Only the single cysteineTLCK and TPCK also modify the E7 protein in vivo in
mutant, cysteine 27 to glycine, remained as an E7 singletkeratinocyte cell lines expressing the E7 protein
following exposure to TPCK and TLCK (Fig. 6B, lanes 1
In order to evaluate if the alteration of the E7 protein and 2). Cysteine 27 is present within the Rb-binding core
is observed only during cell extraction, we tried to modify (residues 25–29) and is important for the binding of Rb
the E7 protein in live cells by adding TLCK or TPCK to protein and for cell transformation.
the tissue culture medium (see Materials and Methods).
As demonstrated in Fig. 4, the in vivo modification of the
TPCK- and TLCK-induced modifications of the E7E7 protein by TLCK was more efficient than its modifica-
protein are specifiction during extraction for immunoprecipitation. While
1200 mM TLCK incompletely modified E7 during cell ex- To verify the established specificity of the TPCK/TLCK
traction (Fig. 3), 250 mM TLCK nearly completely modified reaction, we also evaluated whether other cysteine-con-
E7 in vivo, and 125 mM TLCK in the tissue culture medium taining proteins and zinc-finger proteins could be modi-
was sufficient to modify E7 protein to 50% (Fig. 4). In fied similar to E7. The BPV-1 and HPV-6b E5 proteins
the case of TPCK, a concentration of about 300 mM in were chosen as alternative papillomavirus proteins
the extraction buffer induced 50% modification of the which contained conserved cysteine residues that could
E7 protein (data not shown) while 200 mM was sufficient potentially be chemical targets for modification by TPCK/
to totally modify the E7 protein in vivo. Partial modification TLCK. BPV-1 and HPV-6b E5 proteins (tagged at their
was observed with TPCK concentrations as low as 50 amino-terminus with the AU1 epitope) were transiently
mM in the tissue culture medium (Fig. 4). expressed in COS cells, immunoprecipitated in the pres-
ence and absence of TPCK/TLCK, and evaluated for elec-
Cysteine 27 in the E7 Rb-binding core is essential for
trophoretic mobility. No alterations in electrophoretic mo-
the modification of E7 by TPCK and TLCK
bility were observed following TLCK/TPCK treatment of
these proteins (data not shown). In addition, we ex-We performed an extensive PCR mutagenesis of the
HPV-18 E7 protein in order to define the amino acid resi- pressed a truncated orphan receptor of the glucocorti-
coid family (mitogen-inducible nuclear orphan receptor,due or residues which were essential for its modification
by TPCK/TLCK. In addition to mutating the conserved abbreviated MINOR) (Hedvat and Irving, 1995) which con-
tains three zinc fingers located within its DNA bindingcysteine and histidine residues (the known chemical tar-
AID VY 7780 / 6a12$$$103 02-13-96 00:22:27 viral AP: Virology
549TLCK/TPCK REACT WITH THE HPV-18 E7 PROTEIN
FIG. 5. Diagram of the wild-type HPV-18 E7 protein and the constructed E7rAU1 mutant proteins. The top bar diagram represents the 105-amino-
acid HPV-18 E7 protein and the position of its conserved domains. The position of the Rb-binding core, the casein kinase II phosphorylation sites,
and the zinc-binding domains are indicated. The bottom bars represent the constructed E7 mutants which are compared to the wild-type sequence.
All mutants were appended with the AU1 epitope at the carboxyl-terminus.
domain. The truncated MINOR contains 17 cysteine resi- served with the cysteine 27 mutant protein (Fig. 7A). The
efficiency of the modification of the in vitro-expresseddues and 5 histidine residues as potential TPCK/TLCK
targets. The MINOR protein, tagged at its carboxyl-termi- E7 protein was comparable to the observed E7 protein
modification during cell extraction (Fig. 3). Treatment withnus with AU1, was expressed by a CMV-driven expres-
sion vector in COS cells and was immunoprecipitated by 1.1 mM TLCK (see Materials and Methods) completely
converted in vitro expressed E7 protein to the faster mi-AU1 monoclonal antibody. Similar to the E5 proteins,
there were no detectable changes in MINOR electropho- grating form, whereas no conversion was observed for
the cysteine 27 mutant protein.retic mobility following exposure to TPCK/TLCK (data not
shown). Clearly the TLCK/TPCK-induced modification of The in vitro-expressed, TLCK-modified wild-type E7
protein was then used in an Rb-binding assay. A cellthe E7 protein electrophoretic mobility is not only the
simple consequence of available cysteine/histidine resi- extract of primary human foreskin keratinocytes was
mixed with in vitro-expressed E7 protein which was ei-dues or zinc-finger domains.
ther modified or nonmodified by TLCK. After 12 hr of
Modification by TLCK abolishes the Rb-binding incubation at 47, an immunoprecipitation was carried out
capability of the E7 protein using an anti-Rb monoclonal antibody (see Materials and
Methods). As demonstrated in Fig. 7B, only the nonmodi-
Due to the observed altered electrophoretic properties fied E7 protein was coimmunoprecipitated with the Rb
of TLCK- and TPCK-treated E7 and the involvement of protein. These findings demonstrate that TLCK-depen-
cysteine 27, we analyzed whether this modification of E7 dent modification of the Rb-binding core interferes with
interfered with Rb binding. We expressed the wild-type E7–Rb association.
and the cysteine 27 mutant E7 proteins in a reticulocyte
lysate and analyzed the modification of these proteins
DISCUSSION
by TLCK. In agreement with our earlier observation, the
electrophoretic mobility of in vitro-expressed E7 protein Upon screening HPV-immortalized keratinocytes for vi-
ral early protein expression, we observed that cells con-was altered by TLCK, whereas no modification was ob-
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FIG. 6. (A) Mapping the TLCK/TPCK-reactive site in E7. Lanes 1–4, COS cells were transiently transfected with pSVE7rAU1 plasmid DNA or
control DNA (pSV) as described under Materials and Methods. After [35S]methionine/cysteine labeling, the cells were extracted in RIPA buffer in
the presence (/) or absence (0) of TPCK and TLCK, immunoprecipitated with AU1 monoclonal antibody, and electrophoretically separated on 12%
SDS –polyacrylamide gels. Lanes 1 and 2 show immunoprecipitates of COS cells transfected with pSV (negative control). Lanes 3 and 4 show
immunoprecipitates of COS cells transfected with pSVE7rAU1. E7 doublets are observed only in COS cells transfected with pSVE7rAU1 and
extracted in the presence of TPCK/TLCK (lane 4). A singlet form of E7 was observed when TPCK and TLCK were omitted from the extraction buffer
(lane 3). Molecular weight markers (in kDa) are indicated on the left. Lanes 5–10, COS cells were transfected with vector DNA expressing the
indicated mutant forms of HPV-18 E7 protein (see Fig. 5). AU1 epitopes were appended to the carboxyl-terminus of each of these mutants to
facilitate their detection. Cell labeling, extraction, and immunoprecipitation methods were the same as described for lanes 1–4. Doublet E7 proteins
were observed only in the presence of TPCK/TLCK (lanes 6, 8, and 10). (B) Only the cysteine 27 mutant is resistant to TPCK/TLCK modification.
Vector DNAs expressing the indicated cysteine mutants of E7 were transfected into COS cells, extracted in the presence (/) and absence (0) of
TPCK/TLCK, and evaluated for the presence of doublet forms of E7 protein as described for A. Mutation of cysteine 27, which is central in the E7
Rb-binding core sequence, abrogated the ability of TPCK/TLCK to generate doublet forms of E7 (lane 2). All other cysteine mutant proteins were
converted into doublets (lanes 4, 6, and 8). Molecular weight markers (in kDa) are indicated on the left.
tained an apparent E7 ‘‘doublet’’ rather than a single pro- a modified form of E7 or a cellular protein which was
coprecipitated along with the E7 protein. To resolve thesetein when separated on SDS–polyacrylamide gels. Our
initial hypothesis was that this doublet represented either possibilities, we tagged the E7 gene with the AU1 epitope
FIG. 7. (A) TLCK also reacts with in vitro-expressed E7 protein. The E7rAU1 and the cysteine 27 to glycine E7rAU1 proteins were in vitro
expressed in a reticulocyte lysate, treated with increasing amounts of TLCK (see Materials and Methods), and immunoprecipitated with the AU1
antibody. Only the E7rAU1 protein, and not the cysteine 27 mutant protein, was modified by TLCK. (B) Modification of the E7 protein abrogates its
Rb-binding capability. Aliquots of the in vitro-expressed, TLCK-modified, and nonmodified E7rAU1 protein (A, lanes 4 and 2) were mixed with cell
extracts obtained from primary human foreskin keratinocytes (see Materials and Methods). After an overnight incubation at 47, an immunoprecipitation
was carried out using an anti-Rb antibody, and the immunoprecipitates were electrophoretically separated on a 12% SDS–PAGE gel. Only the
nonmodified E7 protein coimmunoprecipitated with the Rb protein (lane 2) and no E7 protein was precipitated in the absence of keratinocyte extract
(lane 1).
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and showed by Western blotting and immunoprecipita- tein. Finally, none of the cysteines which are involved in
zinc binding were apparent targets for TPCK or TLCK.tion experiments that both proteins in the doublet were
E7. Interestingly, the doublet was generated in vitro dur- These residues are essential not only for E7 dimerization
but also for E7 stability and transforming activity (McIn-ing cell extraction by the exposure of E7 to two serine
protease inhibitors, TPCK and/or TLCK. Similarly, we also tyre et al., 1993).
The Rb-binding core appears essential for TPCK/immunoprecipitated doublet forms of the HPV 16 E7 pro-
tein from TLCK- and TPCK-treated extracts of COS cells TLCK-mediated modification of E7. Although we have not
evaluated direct chemical alkylation in this study, thetransiently expressing HPV 16 E7 (data not shown).
While both TPCK and TLCK have similar effects on the mutagenesis experiments and the known specificities
of TPCK and TLCK for histidine and cysteine residuesmobility of E7, they have variant specificities as protease
inhibitors. TPCK inhibits chymotrypsin and TLCK inhibits suggest that cysteine 27 in the Rb-binding core is at least
one target for alkylation. The proposed modification oftrypsin (Schoellmann and Shaw, 1963; Shaw, 1970; Ste-
venson, 1974). This specificity is conferred by the differ- cysteine in E7 has parallels in the ability of TLCK to
alkylate sulfhydryl groups (probably a cysteine residue)ent sidechains of the protease inhibitors which mimic
the amino acid sidechain of the substrate peptides. How- in the active protein domains of protein kinase C and
cAMP-dependent kinase (Kupfer et al., 1979; Lalou andever, both TPCK and TLCK mediate the irreversible alkyl-
ation of a histidine residue in the active center of these Lederer, 1993). The dependence of the E7 modification
on the Rb-binding core might reflect the tertiary structureproteases (Shaw, 1970). Both protease inhibitors are fur-
ther known to inhibit with less specificity various cysteine of E7. This domain of E7, which is involved in protein –
protein interaction, could be more accessible for TLCK/proteases.
It has been further shown that TPCK and TLCK inhibit TPCK than other domains of the E7 protein, although the
complete TLCK- or TPCK-dependent alteration of the E7the related protein kinase C (Lalou and Lederer, 1993;
Solomon et al., 1985) and the cAMP-dependent kinase protein obtained in live cells indicates that an Rb-bound
E7 protein is not protected from its modification by these(Kinzel and Ko¨nig, 1980; Kupfer et al., 1979). In both of
these cases TLCK seems to be more effective than TPCK chloromethyl ketones. The other potential TLCK/TPCK
target amino acid residues could be protected fromand it is believed that the inhibition is mediated by the
alkylation of a cysteine sulfhydryl group in the enzyme chemical alteration either through steric hindrance (e.g.,
possible E7 dimerization) or because these potential tar-active center. The kinetics and the extent of the inhibition
of protein kinase C are dependent upon the physiological get residues are located in protein domains having a
lower affinity for these chloromethyl ketone derivatives.state of the enzyme. The resting, nonactivated enzyme
is only slowly and incompletely inhibited by TLCK, It is remotely possible that Rb binding core independent
modifications of the E7 protein through TLCK/TPCK dowhereas the activated enzyme is completely inhibited
(Lalou and Lederer, 1993). In addition, activated protein not result in an alteration of the electrophoretic mobility
of the protein, although two human ETS1 proteins showkinase C is protected in a competitive manner from inhi-
bition by TLCK by a substrate (histone III), further sug- a TLCK-dependent alkylation which is accompanied by
an increase in their electrophoretic mobility (Fisher etgesting that TLCK modifies the active center of the pro-
tein. al., 1992). In ETS1 proteins sulfhydryl groups involved in
protein dimerization and their redox potentials appear toWith the exception of cysteine 27, none of the other
tested E7 mutations prevented the increased electropho- regulate the ETS1 TLCK reactivity. Our mutational analy-
sis of the E7 protein might indicate that the alteration ofretic mobility after TPCK/TLCK treatment despite their
having an important effect on E7 activity (based upon the E7 protein is obtained through an affinity labeling
process, indicating the higher affinity of TLCK or TPCKdata from analogous mutations in the HPV-16 E7 protein).
For example, mutation of histidine-2, which decreases for the Rb-binding core than for other E7 protein domains.
As demonstrated by the mutational analysis of the E7E7 transactivational activity and transforming activity on
rodent cells (Banks et al., 1990; Watanabe et al., 1990), protein, the TLCK/TPCK-induced increased electropho-
retic mobility is solely due to the E7 Rb binding corehad no detectable influence on the modifications by the
chloromethyl ketone derivatives TLCK/TPCK. Although dependent modification, indicating the specificity of the
E7 Rb-binding core alteration. This modification abro-this mutant demonstrates a slightly slower migration in
SDS–PAGE, both E7 forms are clearly detected following gates the ability of the E7 protein to interact with the Rb
tumor suppressor protein, a finding which has importanttreatment with TPCK/TLCK. Mutation of leucine 13, which
abrogates E7-mediated transformation of WI 38 human implications for identifying additional E7-associated cel-
lular proteins. Since TPCK and TLCK are commonly usedprimary fibroblasts (Watanabe et al., 1990), also had no
effect on the increased electrophoretic mobility conferred protease inhibitors, their presence in buffers or cell ex-
tracts could interfere with the detection of proteins asso-by the protease inhibitors. Another possible target for
TPCK and TLCK, histidine 59, is well conserved between ciated directly with the Rb-binding domain. The TLCK/
TPCK-induced modification changes the electrophoreticHPV-6b, -11, -16, and -18. A mutant at this residue reacts
with the protease inhibitors similar to wild-type E7 pro- mobility of E7, probably due to structural differences be-
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mortalized human keratinocytes obtained after transfection with hu-tween the modified and the nonmodified E7 proteins.
man papillomavirus type 16 DNA. Oncogene 1, 251–256.Such changes in protein folding or conformational struc-
Dyson, N., Guida, P., Mu¨nger, K., and Harlow, E. (1992). Homologousture could not only be responsible for the observed inabil- sequences in adenovirus E1A and human papillomavirus E7 proteins
ity of modified E7 protein to bind Rb, but could also have mediate interaction with the same set of cellular proteins. J. Virol.
profound effects on the biochemical properties of E7 as 66, 6893–6902.
Dyson, N., Howley, P. M., Mu¨nger, K., and Harlow, E. (1989). The humanwell as its association with other cellular proteins.
papillomavirus-16 E7 oncoprotein is able to bind to the retinoblas-Perhaps the most important finding is the observation
toma gene product. Science 243, 934–937.that E7 protein can be altered in vivo by adding TPCK
Fisher, R. J., Koizumi, S., Kondoh, A., Mariano, J. M., Mavrothalassitis,
and TLCK to the growth medium, suggesting that it might G., Bhat, N. K., and Papas, T. S. (1992). Human ETS1 oncoprotein.
be possible to interfere with the biological activity of E7 Purification, isoforms, –SH modification, and DNA sequence-specific
binding. J. Biol. Chem. 267, 17957–17965.in clinical HPV infections. Since HPV lesions occur on
Gage, J. R., Meyers, C., and Wettstein, F. O. (1990). The E7 Proteins ofexposed skin or mucosal epithelium, it might be possible
the nononcogenic human papillomavirus type 6b (HPV-6b) and ofto apply these inhibitors topically to inactivate E7 and
the oncogenic HPV-16 differ in retinoblastoma protein binding and
thereby prevent tumor formation and potentially interfere other properties. J. Virol. 64, 723–730.
with viral replication. Finally, the finding that E7 contains Green, S., Issemann, I., and Sheer, E. (1988). A versatile in vivo and in
a TPCK/TLCK-reactive site presents a new approach to vitro eukaryotic expression vector for protein engineering. Nucleic
Acids Res. 16, 369.designing and screening for additional pharmacologic
Halbert, C. L., Demers, G. W., and Galloway, D. A. (1991). The E7 genereagents which inactivate E7 function.
of human papillomavirus type 16 is sufficient for immortalization of
human epithelial cells. J. Virol. 65, 473–478.
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